Taken together, these rescue experiments demonstrate that fedratinib suppresses ESCC progression through the JAK2/STAT3 pathway by downregulating vimentin, cyclin D1, and survivin, leading to concurrent inhibition of proliferation and migration, along with induction of apoptosis. This evidence concerns the gene JAK2 and esophageal squamous cell carcinoma.